Physician profile
Felice Lin
NPI 1750646501
$3,766.44
in general payments reported to CMS, 2019-2025
18 companies · $666 in 2025
The $666 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $281 · 2021: $197 · 2022: $433 · 2023: $328 · 2024: $1,341 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235 · Travel and Lodging: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.21 |
| Travel and Lodging | $1,099.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,317.00 | 2019-2025 | Impella |
| Abbott Laboratories | $843.94 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $513.57 | 2019-2025 | |
| Medtronic Vascular, INC. | $182.95 | 2019-2020 | |
| Inspire Medical Systems, INC. | $177.94 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.37 | 2021-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.24 | 2019-2023 | Lifevest |
| Pfizer INC. | $91.72 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $81.13 | 2021-2023 | Verquvo |
| Intuitive Surgical, INC. | $71.94 | 2022 | |
| Boston Scientific Corporation | $67.91 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Janssen Pharmaceuticals, INC | $59.19 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $37.08 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $35.37 | 2023 | Opsumit, Uptravi |
| Cvrx, INC. | $27.20 | 2023 | Barostim Neo System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.90 | 2025 | Amvuttra |
| Novo Nordisk INC | $16.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felice Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.